Stability of botulinum neurotoxin type A, devoid of complexing proteins

Botulinum Journal

Volumn 2, Issue 1, 2011, Pages 49-58

  Grein, Swen ^a   Mander, Gerd J ^a   Fink, Klaus ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

BoNT A; Botulinum neurotoxin type A; Complexing proteins; ICH guideline; Neurotoxin; Stability; Temperature stress

Indexed keywords

BOCOUTURE; BOTULINUM TOXIN A; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FREEZING;

EID: 80051504624     PISSN: 17547326     EISSN: 17547318     Source Type: Journal    
DOI: 10.1504/TBJ.2011.041815     Document Type: Article

References (23)

1. Benecke, R., Jost, W.H., Kanovsky, P., Ruzicka, E., Comes, G. and Grafe, S. (2005) 'A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia', Neurology, Vol. 64, pp.1949-1951. (Pubitemid 40800714)
2. Black, J.D. and Dolly, J.O. (1986) 'Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves', J. Cell. Biol., Vol. 103, pp.521-534. (Pubitemid 16055048)
3. Carruthers, A. (2002) 'Botulinum toxin type A: history and current cosmetic use in the upper face', Dis. Mon., Vol. 48, pp.299-322. (Pubitemid 35007057)
4. Chen, F., Kuziemko, G.M. and Stevens, R.C. (1998) 'Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species', Infect. Immun., Vol. 66, pp.2420-2425. (Pubitemid 28261733)
5. Dolly, J.O., Lawrence, G.W., Meng, J., Wang, J. and Ovsepian, S.V. (2009) 'Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics', Curr. Opin. Pharmacol., Vol. 9, pp.326-335.
6. Dong, M., Yeh, F., Tepp, W.H., Dean, C., Johnson, E.A., Janz, R. and Chapman, E.R. (2006) 'SV2 is the protein receptor for botulinum neurotoxin A', Science, Vol. 312, pp.592-596.
7. Eisele, K.H., Fink, K., Vey, M. and Taylor, H.V. (2010) 'Studies on the dissociation of botulinum neurotoxin type A complexes', Toxicon in press doi:10.1016/j.toxicon.2010.12.019.
8. Goodnough, M.C. and Johnson, E.A. (1992) 'Stabilization of botulinum toxin type A during lyophilization', Appl. Environ. Microbiol., Vol. 58, pp.3426-3428.
9. Göschel, H., Wohlfarth, K., Frevert, J., Dengler, R. and Bigalke, H. (1997) 'Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies - therapeutic consequences', Exp. Neurol., Vol. 147, pp.96-102. (Pubitemid 27402446)
10. Hambleton, P. (1992) 'Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use', J. Neurol., Vol. 239, pp.16-20.
11. ICH Expert Working Group - International Conference on Harmonisation of Technical Reuquirements for Registration of Pharmaceuticals for Human Use (2003) 'Stability testing of new drug substances and products Q1A(R2) guideline', FDA Federal Register, Vol. 68, pp.65717-65718.
12. Jankovic, J. and Brin, M.F. (1991) 'Therapeutic uses of botulinum toxin', N. Engl. J. Med., Vol. 324, pp.1186-1194.
13. Koriazova, L.K. and Montal, M. (2003) 'Translocation of botulinum neurotoxin light chain protease through the heavy chain channel', Nat. Struct. Biol., Vol. 10, pp.13-18. (Pubitemid 36034171)
14. Lacy, D.B., Tepp, W., Cohen, A.C., DasGupta, B.R. and Stevens, R.C. (1998) 'Crystal structure of botulinum neurotoxin type A and implications for toxicity', Nat. Struct. Biol., Vol. 5, pp.898-902. (Pubitemid 28467413)
15. Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. and Binz, T. (2006) 'The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves', FEBS Lett., Vol. 580, pp.2011-2014.
16. Montecucco, C. and Schiavo, G. (1994) 'Mechanism of action of tetanus and botulinum neurotoxins', Mol. Microbiol., Vol. 13, pp.1-8. (Pubitemid 24220537)
17. Roggenkamper, P., Jost, W.H., Bihari, K., Comes, G. and Grafe, S. (2006) 'Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm', J. Neur. Transm., Vol. 113, pp.303-312. (Pubitemid 43201097)
18. Schantz, E.J. and Johnson, E.A. (1992) 'Properties and use of botulinum toxin and other microbial neurotoxins in medicine', Microbiol. Rev., Vol. 56, pp.80-99.
19. Schiavo, G. and Montecucco, C. (1997) 'The structure and mode of action of botulinum and tetanus toxins', in Rood, J.I., MCLane, B.A., Songer, J.G. and Titball, R.W. (Eds.): The Clostridia: Molecular Biology and Pathogenesis, Academic Press Limited, San Diego, CA, USA, pp.295-322.
20. Sesardic, D., Leung, T. and Gaines Das, R. (2003) 'Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin', Biologicals, Vol. 31, pp.265-276. (Pubitemid 37414922)
21. Simpson, L.L., Coffield, J.A. and Bakry, N. (1994) 'Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins', J. Pharmacol. Exp. Ther., Vol. 269, pp.256-262. (Pubitemid 24143262)
22. Wang, S.L., Lin, S.Y., Li, M.J., Wei, Y.S. and Hsieh, T.F. (2005) 'Temperature effect on the structural stability, similarity, and reversibility of human serum albumin in different states', Biophys. Chem., Vol. 114, pp.205-212.
23. Wohlfarth, K., Muller, C., Sassin, I., Comes, G. and Grafe, S. (2007) 'Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins', Clin Neuropharmacol., Vol. 30, pp.86-94. (Pubitemid 46581201)